510(k) Report

510(k) · Cleared

Cleared

Creatinine2

K210452510(k) TraditionalCleared Mar 22, 2022399-day reviewClass II21 CFR 862.1225

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Abbott Ireland Diagnostics Division · CGX Alkaline Picrate, Colorimetry, Creatinine

Cleared on Mar 22, 2022 as substantially equivalent to K083809 (Abbott Laboratories, 2009) after a 399-day review. Its family tree reaches back 3 generations to 1994.

Decided
Mar 22, 2022
Review
399 days
Class
Class II
Product code
CGX
Recalls
None
Predicates
1

Its longest line of descent runs back 3 generations to K941837 (1994). No later device cites it as a predicate yet.

  1. Root · 3 generations backK941837 Roche Reagent for CreatinineRoche Diagnostic Systems, Inc. · 1994
  2. 2 generations backK061193 CreatinineAbbott Laboratories, Inc. · 2006
  3. 1 generation backK083809 CreatinineAbbott Laboratories · 2009
  4. This deviceK210452 Creatinine2Abbott Ireland Diagnostics Division · 2022
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−3K941837Roche Reagent for CreatinineRoche Diagnostic Systems, Inc.1994—
−2K061193CreatinineAbbott Laboratories, Inc.2006—
−1K083809CreatinineAbbott Laboratories2009—
0 (this device)K210452Creatinine2Abbott Ireland Diagnostics Division2022—
FIG. 1 — Lineage of K210452, 1994–2022Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in CGX? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new CGX device

  1. #1 K242685 Atellica® CH Creatinine_3 (Crea3)score 12.1 · 3 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K083809Creatinine
Summary page 5
…n: Class II Classification Name: Creatinine test system Governing Regulation Number: 21 CFR 862.1225 Product Code: CGX IV. Predicate Device Creatinine (k083809) V. Description of Device A. Principles of the Procedure The Creatinine2 assay is an automated clinical chemistry…
Abbott Laboratories2009—

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 28 years and passes through 4 companies; a new generation was cleared every 11.8 years on median.
  • None of the 3 ancestors has a recall.

How does its category compare?

All CGX devices

CGX Alkaline Picrate, Colorimetry, Creatinine: FDA decisions, review times, recalls and adverse event reports over 20 years. 2022, this device’s year, is highlighted.

FDA decisions per year · CGX

1in 2025

2007: 42009: 12012: 12013: 12014: 22016: 12022: 12024: 22025: 12026 (partial year): 1
2007high 4 (2007) · low 0 (2008)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · CGX

25in 2007

2007: 25 days median
2007high 25 (2007)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · CGX

2in 2016

2008: 12009: 22010: 22011: 12012: 22016: 22026 (partial year): 1
2007high 2 (2009) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · CGX

34in 2025

2007: 152008: 272009: 52010: 52011: 322012: 132013: 242014: 132015: 132016: 32017: 212018: 142019: 252020: 192021: 132022: 232023: 192024: 322025: 34
2007high 34 (2025) · low 3 (2016)2025

MAUDE reports naming product code CGX, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
2007425015
20080—127
20091—25
20100—25
20110—132
20121—213
20131—024
20142—013
20150—013
20161—23
20170—021
20180—014
20190—025
20200—019
20210—013
20221—023
20230—019
20242—032
20251—034
20261—1—

What is it indicated for?

The Creatinine2 assay is used for the quantitation of creatinine in human serum, plasma, or urine on the ARCHITECT c System.

The Creatinine2 assay is to be used as an aid in the diagnosis and treatment of renal diseases, in monitoring renal dialysis, and as a calculation basis for measuring other urine analytes.

Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.

Cite this page

510(k) Report. “K210452: Creatinine2.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K210452

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026